Positioning political selling, disclosed 2026-09-25
Options put/call open interest 0.37, read 2026-11-07
Ethical does not pass the values gate
Price24.39 USD
Fair value34.06
Ethical score10.0/100
Value readUndervaluedas of 6 Nov 2026
Our investment reviews on this name
2026-10-29Read Markup22.69+7.5% to today ✓Markdown gives way to Markup first Markup read since August
2026-10-11Read Markdown21.91+11.3% to today Distribution gives way to Markdown first Markdown read since July
2026-10-02Read Distribution21.91+11.3% to today Markup gives way to Distribution after a 17% slide in 6 weeks
2026-08-24Read Markup26.42-7.7% to today Markdown gives way to Markup after an 11% rise in 8 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Comcast holds its Markup at $24.39. The statistical read favours the buyers, held for 37 days.
As held on the ledger · 2026-11-06
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 37 days
Price at the screen
$24.39
Valuation
7.05 trailing · 6.32 forward price to earnings
Values screen
FAIL· score 10.0
Beta
0.67
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
36.29%
Below 33%
Interest-bearing debt is 36.3% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
2.92%
Below 33%
Cash held in interest-bearing accounts and securities is 2.9% of assets, under the one-third limit.
Pass
Receivables
8.56%
Below 49%
Money owed to the company is 8.6% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Comcast's business is in a permissible area, but its interest-bearing debt is about 36% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CMCSA's ethical verdict changes
Today CMCSA does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 6 Nov 2026: it trades at roughly a 28% discount to our $34.06 fair value, moderate competitive moat.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. A 28.4% discount to the base estimate.
Where our models see it going: fair-value estimate $34.06, with a range of $34.06 to $48.78, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Comcast pipes the bills but carries too much debt
Comcast pipes internet and shows into homes across America, yet the balance sheet carries more debt than we can stomach. We are staying away, for one clear reason that has nothing to do with subscriber numbers or theme parks. The ethical screen flags the debt ratio straight away. This is exactly what the screen is for.
The shares trade at 6.4 times forward earnings with revenue growing 5 percent and a 15 percent profit margin, yet that leverage outweighs the 21 percent ROE and moderate moat in our view. Twenty one analysts sit on hold with a median target of 31 dollars, well below our own fair value.
Risk sits in rising interest costs on the debt pile and any slowdown in broadband adds or studio releases that could crimp the cash flow. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CMCSA trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Markup$24.85+9.5%Entry 23
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 9.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (22 analysts) rates it hold, with a mean price target of $28.
2026-10-29Markup · changed$22.69+4.2%Entry 22
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (22 analysts) rates it hold, with a mean price target of $28.
2026-10-22Markdown$21.77+0.0%Entry 21
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (22 analysts) rates it hold, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Markdown$21.77+0.0%Entry 20
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (22 analysts) rates it hold, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-20Markdown$21.77+0.0%Entry 19
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (22 analysts) rates it hold, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-19Markdown$21.77+0.0%Entry 18
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (22 analysts) rates it hold, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Markdown$21.77+0.0%Entry 17
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (22 analysts) rates it hold, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-17Markdown$21.77+0.0%Entry 16
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (22 analysts) rates it hold, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-16Markdown$21.77+5.4%Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 5.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (22 analysts) rates it hold, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-15Markdown$20.66-5.7%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 5.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (22 analysts) rates it hold, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
